NEUROPHARMACOLOGICAL APPROACHES TO THE TREATMENT OF NEURODEGENERATIVE DISORDERS
Keywords:
neuropharmacology; neurodegeneration; Alzheimer disease; Parkinson disease; amyotrophic lateral sclerosis; neuroinflammation; antisense oligonucleotides; gene therapy; blood-brain barrier.Abstract
Neurodegenerative disorders are characterized by progressive dysfunction and loss of selectively vulnerable neuronal populations, yet their molecular drivers extend beyond neuronal death to include protein misfolding, synaptic failure, mitochondrial dysfunction, excitotoxicity, impaired proteostasis, neuroinflammation and disruption of brain-barrier homeostasis. The objective of this structured review was to evaluate contemporary neuropharmacological approaches for Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis and related disorders, with emphasis on the transition from symptomatic neurotransmitter replacement toward disease-modifying and precision strategies. International literature published predominantly between 2020 and 2025 was synthesized using an IMRAD-oriented framework. Current symptomatic therapies remain clinically important: cholinesterase inhibitors and memantine are used in Alzheimer disease, while levodopa and adjunct dopaminergic agents remain central to Parkinson disease. However, recent clinical evidence supports disease-modifying potential in selected populations through anti-amyloid monoclonal antibodies, and target-specific RNA therapy has established a mechanistic precedent in SOD1-associated amyotrophic lateral sclerosis. Emerging approaches include tau- and α-synuclein-directed interventions, microglial and immune modulation, synapse-protective pharmacology, gene therapy, antisense oligonucleotides and engineered delivery systems that improve central nervous system exposure. The major future challenge is to match mechanism, disease stage, molecular phenotype and delivery technology while maintaining an acceptable benefit-risk profile. Precision neuropharmacology is therefore expected to integrate biomarkers, genetics and adaptive treatment monitoring rather than rely on a single disease-wide pharmacological strategy.
References
1. Singh, K., Gupta, J. K., Kumar, S., & Soni, U. (2024). A review of the common neurodegenerative disorders: Current therapeutic approaches and the potential role of bioactive peptides. Current Protein & Peptide Science, 25(7), 507–526. https://doi.org/10.2174/0113892037275221240327042353
2. van Dyck, C. H., Swanson, C. J., Aisen, P., et al. (2023). Lecanemab in early Alzheimer’s disease. New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
3. Sims, J. R., Zimmer, J. A., Evans, C. D., et al. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512–527. https://doi.org/10.1001/jama.2023.13239
4. Höllerhage, M., Becktepe, J., Classen, J., et al. (2024). Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: Guideline “Parkinson’s disease” of the German Society of Neurology. Journal of Neurology, 271, 7071–7101. https://doi.org/10.1007/s00415-024-12632-6
5. Miller, T. M., Cudkowicz, M. E., Genge, A., et al. (2022). Trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal of Medicine, 387, 1099–1110. https://doi.org/10.1056/NEJMoa2204705
6. Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023). Tau-targeting therapies for Alzheimer disease: Current status and future directions. Nature Reviews Neurology, 19, 715–736. https://doi.org/10.1038/s41582-023-00883-2
7. Park, H., Kam, T.-I., Dawson, V. L., et al. (2025). α-Synuclein pathology as a target in neurodegenerative diseases. Nature Reviews Neurology, 21, 32–47. https://doi.org/10.1038/s41582-024-01043-w
8. Gao, C., Jiang, J., Tan, Y., et al. (2023). Microglia in neurodegenerative diseases: Mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy, 8, 359. https://doi.org/10.1038/s41392-023-01588-0
9. Dejanovic, B., Sheng, M., & Hanson, J. E. (2024). Targeting synapse function and loss for treatment of neurodegenerative diseases. Nature Reviews Drug Discovery, 23, 23–42. https://doi.org/10.1038/s41573-023-00823-1
10. Weiner, H. L. (2025). Immune mechanisms and shared immune targets in neurodegenerative diseases. Nature Reviews Neurology, 21, 67–85. https://doi.org/10.1038/s41582-024-01046-7
11. Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023). AAV-based in vivo gene therapy for neurological disorders. Nature Reviews Drug Discovery, 22, 789–806. https://doi.org/10.1038/s41573-023-00766-7
12. Gao, J., Gunasekar, S., Xia, Z. J., et al. (2024). Gene therapy for CNS disorders: Modalities, delivery and translational challenges. Nature Reviews Neuroscience, 25, 553–572. https://doi.org/10.1038/s41583-024-00829-7
